Top of this page
Skip navigation, go straight to the content

Our Science Pipeline
 

R&D pipeline

 

The UCB pipeline delivers:

  •  a promising portfolio targeting severe diseases and addressing unmet medical needs
  •  focus on neurological and immunological diseases
  •  more convenient and effective treatments for patients and specialists.


  Indications Phase 1 Phase 2 Phase 3 Filing
bimekizumab (IL17AF)psoriasisphase 3
 psoriatic arthritisphase 3 half
 axial spondyloarthritis
phase 3 half
 hidradenitis suppurativa
phase 3 half
zilucoplan (C5)myasthenia gravisphase 3 half
 immune-mediated necrotizing myopathy (IMNM)phase 2 half
rozanolixizumab (FcRn)myasthenia gravisphase 3 half
 immune thrombocytopeniaphase 3 half
 chronic inflammatory demyelinating polyneuropathy (CIDP)phase 2 half
dapirolizumab pegol (CD40L)systemic lupus erythematosus1phase 3 half
Staccato® alprazolamactive epileptic seizurephase 2
UCB0107
progressive supranuclear palsy (PSP)phase 1
4 Projects phase 1 half

1 In partnership with Biogen